“We’ve pulled together a very unique combination of resources which positions us very strongly to do drug development in a really rapid, novel and accelerated way,” said CEO, Dr Michael Winlo on Reach Markets’ webcast series ‘The Insider’.
“Our data is essentially the brains behind our operation. It allows us to do intelligent care delivery and very intelligent, highly strategic drug design,” he said.
“Our goal is to try to move the best products from medicinal cannabis into mainstream medicine, registered products that then can be available through a routine prescription,” he added.
31st May 2024
8th May 2024
4th May 2024
Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)
including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.
Please click here to read our full warning.